SSG
KLRS

Summit Securities Group’s Kalaris Therapeutics KLRS Stock Holding History

Summit Securities Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-873
Closed -$43K – 959
2023
Q3 		$43K Buy
+873
New +$59.5K ﹤0.01% 297

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Summit Securities Group's KLRS Position: Q4 2023 in Review

Summit Securities Group sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 873 shares — an estimated $43K sold.

Summit Securities Group first reported a position in KLRS in Q3 2023 and held it in 1 quarter. The position peaked at $43K in Q3 2023. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • Summit Securities Group reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Summit Securities Group sold 873 Kalaris Therapeutics shares in Q4 2023, an estimated $43K.
  • Summit Securities Group first reported a position in Kalaris Therapeutics in Q3 2023 and held it in 1 quarter.
  • Summit Securities Group's Kalaris Therapeutics position peaked at $43K in Q3 2023.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on Summit Securities Group's 13F filing for Q4 2023, filed 14 Feb 2024.